Skip to contentC
Chemed Corp
C
CHEChemed Corp Q3 2024 · 10-Q
Revenue$391.41M$391.41M+17.3% vs Q3 2023 Net Income$75.78M$75.78M+1.1% vs Q3 2023 EPS Diluted$5.00$5.00+1.4% vs Q3 2023 Operating Income$92,157,000+6.1% Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Chemed Corp · CIK 19584 · Engraved from SEC EDGAR
derived
Free Cash Flowderived$76,973,000+345.7% Margins · derivedOperating margin23.5%−2.5 pt vs Q3 2023
Net margin19.4%−3.1 pt vs Q3 2023
ended Sep 30, 2024 · filed Nov 1, 2024 · 32 d after period end